Bandaram Pharma Packtech Reports Q2 FY26 Loss of Rs. 34.74 Lakhs Amid Revenue Decline

Bandaram Pharma Packtech Limited , formerly known as Shiva Medicare Limited, has reported a net loss of Rs. 34.74 lakhs for the quarter ended September 30, 2025 (Q2 FY26), according to the company's latest financial results. This marks a significant downturn from the profit of Rs. 67.19 lakhs recorded in the same quarter of the previous year.

Revenue Decline

The company's standalone revenue from operations saw a substantial decrease, falling to Rs. 32.93 lakhs in Q2 FY26 from Rs. 316.61 lakhs in the corresponding quarter of the previous year. This represents a year-on-year decline of approximately 89.6% in revenue.

Financial Performance Overview

Here's a breakdown of the key financial metrics for Q2 FY26:

Particulars (Standalone)	Q2 FY26 (Rs. Lakhs)	Q2 FY25 (Rs. Lakhs)	YoY Change
Revenue from Operations	32.93	316.61	-89.6%
Total Income	33.76	316.61	-89.3%
Total Expenses	68.50	283.53	-75.8%
Net Profit/(Loss)	(34.74)	67.19	-151.7%

Expense Management

Despite the significant drop in revenue, Bandaram Pharma Packtech managed to reduce its total expenses by 75.8% year-on-year, from Rs. 283.53 lakhs in Q2 FY25 to Rs. 68.50 lakhs in Q2 FY26. However, this reduction in expenses was not sufficient to offset the sharp decline in revenue.

Half-Yearly Performance

For the six months ended September 30, 2025, the company reported:

Total income of Rs. 109.50 lakhs, down from Rs. 588.76 lakhs in the same period last year
Net loss of Rs. 61.63 lakhs, compared to a profit of Rs. 8.22 lakhs in the previous year

Consolidated Results

On a consolidated basis, the company fared slightly better:

Q2 FY26 consolidated revenue stood at Rs. 1,372.48 lakhs, up from Rs. 710.83 lakhs in Q2 FY25
Consolidated net profit for Q2 FY26 was Rs. 6.02 lakhs, though lower than the Rs. 67.19 lakhs reported in Q2 FY25

Balance Sheet Highlights

As of September 30, 2025, Bandaram Pharma Packtech reported:

Total assets of Rs. 1,663.63 lakhs, down from Rs. 1,920.97 lakhs as of March 31, 2025
Total equity (including share capital and other equity) of Rs. 1,148.66 lakhs, compared to Rs. 1,210.25 lakhs at the end of the previous fiscal year

The financial results indicate a challenging quarter for Bandaram Pharma Packtech, with a significant decline in revenue and a shift from profit to loss in the standalone results. However, the consolidated performance shows some resilience with increased revenue, albeit with reduced profitability compared to the previous year.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-4.99%	+10.85%	+49.67%	-4.59%	-12.51%	+60.23%

Bandaram Pharma Packtech Limited has announced a significant corporate action, involving a substantial acquisition of equity shares by its promoters and persons acting in concert.

Key Details of the Share Acquisition

Prajitha Bandaram acquired 486,480 shares through preferential allotment on November 6, 2025.
The company's equity share capital increased from Rs. 12.00 crores (1.20 crore shares of Rs. 10 each) to Rs. 17.97 crores (1.79 crore shares of Rs. 10 each) after the acquisition.

Promoter Group Holdings

Following this acquisition, the promoter group's holdings include:

Promoter Name	Number of Shares
Prajitha Bandaram	486,480
Satyavathi Bandaram	1,880,000
B Premsai Reddy	1,880,000
M. Seetharama Reddy	112,500

Regulatory Compliance

The disclosure was filed under SEBI regulations for substantial acquisition of shares and takeovers, ensuring transparency in the company's ownership structure.

Implications

This move by Bandaram Pharma Packtech's promoters indicates a commitment to the company. The change in shareholding structure may potentially influence the company's operations and decision-making processes.

Stakeholders may observe how Bandaram Pharma Packtech utilizes this increased promoter stake in its future strategies and market positioning within the pharmaceutical packaging industry.